Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.
Lead Product(s): Glucarpidase
Therapeutic Area: Pharmacology/Toxicology Product Name: Megludase
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BTG Specialty Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021